Interstitial lung disease (ILD) refers to a group of lung diseases affecting the interstitium. It is associated with wide spread inflammation and fibrosis of the alveolar walls, compromising alveoli function and gas exchange. Idiopathic Pulmonary Fibrosis (IPF) is one of the most major types of ILD.

IPF is believed to be associated with aberrant wound healing and the excessive deposition of collagen in the pulmonary interstitium, with minimal associated inflammation. The 5-year survival rate of individuals affected with IPF is roughly 20%, aetiology is idiopathic with familial IPF accounting for just 5% of cases.

Standard treatments for IPF include anti-fibrotic and anti-inflammatory drugs, with the goals of treatment being alleviation of some of the symptoms, reducing speed of propagation and preventing acute exacerbations.

IAG’s team experience in clinical trials focuses on the patient stratification and finding the optimal imaging based endpoints to assess the treatment induced changes.

At patient stratification, we focus on assisting physicians with distinguishing I{F patients from those with COPD and asthma. Usually it involves collaboration within a multi-disciplinary team of a pulmonologist, radiologist and pathologist.

IAG’s radiology team has extensive experience with using High Resolution Computed Tomography (HRCT) to characterize and classification patients with lung diseases. This modality can be utilized without the use of contrast agents and can image slices up to a resolution of 1-2mm revealing detail of the entire ling parenchyma. The HRCT imaging findings obtained usually complement the histologic findings on post-mortem/biopsy.

To assess the impact of a novel therapy, IAG’s team bring knowledge of qualitative and quantitative systems to assess:

  • Pure ground glass opacity,
  • Lung fibrosis,
  • Honeycombing,
  • Emphysema.

IAG’s team are activity contributing to the research in lung diseases and led development of novel methodologies and scoring using advanced imaging, including MRI and molecular imaging

Reach out to our expert team, as you are designing and planning your trial.

About IAG, Image Analysis Group

IAG is a unique partner to life sciences companies developing new treatment and driving the hope of the up-coming precision medicine. IAG leverages expertise in medical imaging and the power of DYNAMIKA™, our proprietary cloud-based platform, to de-risk clinical development and deliver lifesaving therapies into the hands of patients much sooner. IAG provides early drug efficacy assessments, smart patient recruitment and predictive analysis of advanced treatment manifestations, thus lowering investment risk and accelerating study outcomes.

Acting as imaging Contract Research Organization, IAG’s experts also recognize the significance of a comprehensive approach to asset development. They actively engage in co-development projects with both private and public sectors, demonstrating a commitment to cultivating collaboration and advancing healthcare solutions.

Contact our expert team:

Experience: Scoring Systems
  • Semi-Quantitative Scoring
  • Quantitative Lung Fibrosis Score
Experience: Imaging
  • High Resolution Computed Tomography (HRCT)
  • MRI
  • PET

Since 2007, over 2000 articles were published to cover scientific discoveries, technology break-throughs and special cases. We list here some critically important papers and abstracts.


Combining our technologies and business advisory services with promising life science companies has yielded spectacular results over the past five years. As a trusted partner to many biotech and pharma companies, IAG’s team is proud to share your words and quotes.